A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation safeguards at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can vary from causing mild cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs working hard, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by stimulating the mother’s body’s defences to produce defence proteins, which are then passed to the developing baby through the placenta. This mother-derived protection offers newborns with instant defence from the moment of birth, precisely when they are highly susceptible to RSV. The new study demonstrates that protection reaches nearly 85 per cent when the vaccine is administered at least four weeks before delivery. Even briefer gaps between vaccination and birth can still deliver meaningful protection, with evidence suggesting that a two-week gap is adequate to shield babies born slightly early. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst noting that protection can still occur even if given later in the third trimester.
- Nearly 85 per cent protection when vaccinated 4 weeks before birth
- Maternal antibodies transferred through the placenta safeguard newborns from birth
- Protection possible with two-week gap before premature birth
- Vaccination during third trimester still offers meaningful protection for infants
Strong evidence from current research
The performance of the RSV vaccine administered during pregnancy has been demonstrated through a extensive research programme conducted across England, analysing data from close to 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that six-month timeframe, providing robust and representative evidence of the vaccine’s practical effectiveness. The study’s conclusions have been endorsed by the UK Health Security Agency as showing “excellent protection” for newborns during their earliest and most vulnerable period. The breadth of this investigation gives healthcare professionals and parents-to-be with confidence in the vaccine’s demonstrated effectiveness across diverse populations and circumstances.
The results reveal a striking picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not received the vaccination. This marked difference emphasises the vaccine’s essential role in preventing serious illness in newborns. The drop in hospital admissions surpassing 80 per cent represents a major public health success, helping to prevent thousands of infants from experiencing the distressing and potentially serious symptoms connected with severe RSV infection. These findings reinforce the importance of the vaccination programme launched in the UK in 2024.
Methodology and scope of study
The research examined birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection rates and hospital admissions. The sizeable sample and thorough nature of the data collection ensured that findings were statistically significant and reflective of the wider population, rather than isolated cases or small subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had been given the vaccine at varying intervals before delivery. This allowed researchers to establish the least amount of time between vaccination and birth for maximum protection, as well as to determine whether protection remained meaningful with reduced timeperiods. The methodology captured practical outcomes rather than laboratory-based settings, providing practical evidence of how the vaccine works when given across varied healthcare environments and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and the dangers
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity changing substantially from minor cold-type symptoms to serious, potentially fatal chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during busier periods.
The infection produces deep inflammation in the lungs and airways, making it perilously hard for vulnerable newborns to feed and breathe adequately. Parents frequently observe their babies visibly struggling, their chests rising whilst they work to get adequate oxygen into their weakened respiratory system. Whilst most newborns recover with supportive care, a small but significant proportion perish from respiratory syncytial virus complications annually, making immunisation programmes a vital health service priority for protecting the most vulnerable and youngest individuals in the population.
- RSV produces inflammation in lungs, resulting in serious respiratory problems in infants
- Nearly 50% of newborns catch the virus in their first few months of life
- Symptoms range from mild colds to life-threatening chest infections requiring hospitalisation
- More than 20,000 UK infants require serious hospital care for RSV annually
- Small numbers of infants succumb to RSV related complications each year in the UK
Adoption rates and professional guidance
Since the RSV vaccine programme began in 2024, health officials have stressed the significance of pregnant women getting their jab at the optimal time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing matters greatly for guaranteeing newborns benefit from the maximum immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery offers approximately 85% protection, experts recommend women to get their vaccine as soon as feasible from 28 weeks of pregnancy onwards to maximise the antibodies transferred to their babies via the placenta.
The messaging from health authorities remains clear: pregnant women should prioritise vaccination during their final three months, even if circumstances mean they cannot receive the jab at the ideal window. Dr Watson has provided reassurance to pregnant women that protection remains still achievable with reduced timeframes between vaccination and birth, including even a two-week gap for those delivering slightly early. This flexible approach acknowledges the practical demands of pregnancy whilst ensuring strong safeguarding for vulnerable newborns during their earliest and most vulnerable period when RSV represents the highest danger of severe infection.
Regional disparities in vaccine uptake
Whilst the RSV vaccine programme has been launched across England, uptake rates and implementation timelines have differed across different regions and NHS trusts. Some areas have attained greater immunisation rates among qualifying expectant mothers, whilst others remain focused to boost understanding and access to the jab. These regional differences demonstrate variations in medical facilities, communication strategies, and community involvement initiatives, though the overall statistics demonstrates consistently strong protection irrespective of geographical location.
- NHS trusts launching diverse outreach initiatives to engage with expectant mothers
- Inconsistencies across regions in vaccination coverage levels across England demand focused enhancement
- Local healthcare systems modifying schemes to suit community needs and circumstances
Real-world impact and parental perspectives
The vaccine’s remarkable effectiveness translates into tangible benefits for families throughout the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV before the rollout of this safeguarding intervention, the 80% reduction in admissions means thousands of infants spared from serious illness. Parents no longer face the troubling prospect of watching their newborns struggle for breath or labour to feed, symptoms that define critical RSV illness. The vaccine has markedly changed the picture of neonatal respiratory health, providing expectant mothers a preventative option to safeguard their most at-risk babies during those critical early months.
For families like that of Malachi, whose acute RSV infection resulted in profound brain damage, the vaccine’s availability carries profound emotional significance. His mother’s advocacy for the jab emphasises the life-altering consequences that vaccine-preventable disease can inflict on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story strikes a chord with parents now given protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has provided considerable reassurance to expectant mothers navigating their late pregnancy, transforming what was once an predictable seasonal threat into a manageable risk.